The drugmaker plans to shed noncore assets. While those assets are undisclosed, Takeda said it plans to prioritize treatments in gastroenterology, oncology and rare diseases if the deal is approved.
Shareholders are slated to vote on the deal Dec. 5. Two-thirds of shareholders must support the proposal for it to move forward.
If the $62 billion transaction wins approval, the combined company would have $31 billion in revenue, which places it among the top 10 within the global pharmaceutical industry, behind industry leaders Johnson & Johnson and Pfizer.
More articles on pharmacy:
Teva launches generic EpiPen for $300
Bayer considers sale of consumer health brands
Unilever wants to buy GlaxoSmithKline’s nutrition business: 5 things to know
